One Lot of Adbry Recalled

On Feb. 12, 2026, LEO Pharma initiated a voluntary US recall of Adbry^® (tralokinumab ldrm) 300 mg/2mL single dose autoinjector. The recall was prompted by the identification of particulate matter in a single unit from the affected lot, which laboratory testing determined to be wool fiber, raising concerns for potential patient exposure to foreign material. Adbry is approved for the treatment of moderate‑to‑severe atopic dermatitis in adult and pediatric patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. For recall information, see here.